CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease
 
CERAD

Order Form

Download Printable Order Form

Following its organization in 1986, the Consortium to Establish a Registry for Alzheimer’s Disease enrolled 24 university medical centers in the U.S. engaged in Alzheimer’s disease (AD) research. The purpose of this consortium at that time was to develop brief, standardized and reliable procedures for the evaluation and diagnosis of patients with AD and other dementias of the elderly. These procedures included data forms, flipbooks, guidebooks, brochures, instruction manuals and demonstration tapes, which are now available for purchase. The CERAD assessment material can be used for research purposes as well as for patient care.

Purchase orders should be accompanied by a brief description of the proposed use of the assessment instruments, the approximate number of subjects to be tested each year as well as plans, if any, for publication. CERAD material purchased by the approved applicant is restricted to his or her use only and must not be sold or redistributed to others without authorization.

CERAD has developed several basic standardized instruments, each consisting of brief forms designed to gather data on normal persons as well as on cognitively impaired or behaviorally disturbed individuals. Such data permit the identification of dementia based on clinical, neuropsychological, behavioral or neuropathological criteria.

Staff at participating CERAD sites were trained and certified to administer the assessment instruments and to evaluate the subjects enrolled in the study. Cases and controls were evaluated at entry and annually thereafter including (when possible) autopsy examination of the brain to track the natural progression of AD and to obtain neuropathological confirmation of the clinical diagnosis. The CERAD data base has become a major resource for research in Alzheimer’s disease. It contains longitudinal data for periods as long as seven years on the natural progression of the disorder as well as information on clinical and neuropsychological changes and neuropathological manifestations.


Product Discriptions

1. Clinical/Neuropsychological Assessment for Alzheimer’s Disease - $70
The clinical forms request information from the subject (and, where appropriate, from a knowledgeable informant) regarding the patient’s clinical history, systemic disorders, cerebrovascular disease, parkinsonism, depression, the Blessed Dementia Rating Scale, Short Blessed Test, calculation, clock and language tests, physical examination, laboratory studies, the Clinical Dementia Rating scale and finally, a diagnostic impression of either AD alone, AD associated with other disorders or non-AD dementia.

The neuropsychological assessment includes measures of verbal fluency, confrontational naming (15-item Boston Naming Test), the Mini-Mental State examination, measures of verbal learning, recall and recognition, and constructional praxis performance and recall.


Spiral-Bound Flipbooks: For use with neuropsychological battery -$30 each

1A. Modified Boston Naming Test : 15 line drawings for identification
1B. Word List Memory, Recall and Recognition Test

2. CERAD Video Demonstration - $75 each

A- Administration of the Neuropsychological Battery (DVD)
B- Demonstration of Behavior Rating Scale for Dementia (VHS Tape)
C- French Language Tape: Administration de la Batterie Neuropsychologique (VHS Tape)

3. CERAD Neuropathological Assessment for Alzheimer’s Disease - $90
This assessment is a highly respected instrument which is widely used in the U.S. and abroad for clinical studies of AD and other progressive dementias of the elderly. Its purpose is to establish more accurate and standardized neuropathological criteria for the diagnosis of AD. It is a practical protocol for post-mortem examination of the brain and provides measures for determining the neuropathological spectrum and heterogeneity of AD and other dementias. This assessment packet includes forms for collecting information on demographic data and gross and microscopic findings on cerebrovascular disease. It also includes an assessment of the neurohistological findings and final neuropathological diagnoses. It is accompanied by a detailed manual, the CERAD Guide to Neuropathological Assessment of AD and Other Dementias.

4. The Behavior Rating Scale for Dementia (BRSD) - $85
This assessment is a standardized instrument for rating behavioral abnormalities in demented or cognitively impaired individuals. Items are scaled according to their frequency of occurrence. The scale is informant-based and consists of 46 items which can be categorized into clinically relevant domains, i.e., depressive features, psychotic symptoms, behavioral dysregulation, irritability/agitation, vegetative features, aggression and affective lability. A shorter 17 item version is also available. The BRSD includes an additional packet containing a comprehensive instruction manual including results of factor analysis, scoring forms, scoring tables, instructions to informant and response cards.


5. Assessment of Service Needs of Patients with Dementia - $25

A questionnaire is available for caregivers of subjects with AD. It assesses the need and extent of use of the most common services required for care of persons with dementia. The questionnaire includes questions on the caregiver’s current situation, day and over-night care for the patient outside the home and care of the patient at home.

6. Autopsy Resource Packet - $20
This is a set of guidelines, sample correspondence, and forms available for medical centers interested in obtaining brain autopsies. It includes educational pamphlets designed to encourage autopsy examination.

7. CD-ROM: The CERAD Database and Assessment Instruments - $600
The CERAD study population includes 1094 patients with a clinical diagnosis of AD and 463 control subjects who were enrolled at 24 university medical centers in the U.S. These patients and controls were evaluated annually between 1987 and 1996. The resulting longitudinal data include clinical findings and neuropsychological test scores, behavioral manifestations of dementia, time to death or admission to a nursing home and neuropathological findings. Standardized neuropathological confirmation of the clinical diagnosis was made at autopsy in approximately half of the decedents.

The CD-ROM contains:
- The complete CERAD dataset;
- CERAD assessment batteries: data-gathering forms and testing instructions;
- Condensed versions of the data forms with variable names;
- Selected ancillary and educational materials;
- A Manual of Operations giving the history of the CERAD study and information on the database.

Shipping and handling costs will be added to all orders. Prices are current as of March 2009 but are subject to change at any time.

Please contact CERAD for information regarding the availability of CERAD assessment instruments in additional languages, e.g., Bulgarian, Chinese, Dutch, Finnish, French, German, Italian, Japanese, Korean, Arabic, Norwegian, Portuguese, Spanish.

CERAD
Box 3003
Center for the Study of Aging and Human Development
Duke University Medical Center
Durham, NC 27710
FAX #: (919) 668-0453
PHONE #: (919) 660-7530
e-mail address: ldg@geri.duke.edu, ggf@geri.duke.edu

Download Printable Order Form

Download Printable version of this page.

Center for the Study of Aging and Human Development, Duke University Medical Center

Copyright © 2005